ClinicalTrials.gg
TerminatedNCT02907177POINTUpdated May 18, 2021Results posted

Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)

A Phase 3 interventional study of Ponesimod and Placebo in Multiple Sclerosis, sponsored by Actelion. Terminated at 119 sites in 20 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2021-05-18.

Sponsored by Actelion (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Why this study was terminated
sponsor decision due to low recruitment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,192 studies in Multiple Sclerosis with a site in United States — 184 open to participants now, 259 under way, 23 of them phase 3. Multiple Sclerosis · United States.

Enrollment
203rd of 879
136 · median 50
Started
2017
with 59 others
Phase 3
127 of 1,192
8 open now
Registered
555th of 1,192
by date

Among the 1,192 studies in Multiple Sclerosis with a site in United States, this one is the 203rd largest by enrollment of the 879 interventional ones that give a count, is one of 60 that started in 2017, is one of 127 in phase 3, and was the 555th registered.

Multiple Sclerosis

3,269 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

184 of the 1,192 studies in Multiple Sclerosis with a site in United States are open now. Recruiting first, the newest first:

179 more — sign in →

All 184 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,192 studies in Multiple Sclerosis with a site in United States, or all of them as a file.
02

Study summary

This clinical study compares the efficacy, safety, and tolerability of therapy with ponesimod vs placebo in subjects with active RMS who are treated with DMF (Tecfidera®).

Read the detailed description

The study will assess the efficacy, safety, and tolerability of add-on therapy with ponesimod 20 mg vs placebo in adult participants with active relapsing multiple sclerosis (RMS) who are treated with dimethyl fumarate (DMF). Approximately 600 participants who have been receiving DMF for at least 6 months will be randomized in a 1:1 ratio to ponesimod 20 mg or placebo. The study consists of the following study periods: Pre-randomization period; Treatment period; Post-treatment observation period. The study includes one ponesimod treatment arm at the maintenance dose of 20 mg o.d. corresponding to the optimal dose when used as monotherapy based on the Phase 2 dose-finding trial and its ongoing extension. The study includes a placebo comparator arm, but all patients will remain on DMF background therapy throughout the study. Moreover, participants who experience a confirmed relapse or an event of 24-week confirmed disability accumulation (DMF) while on study drug will have the option to switch to an alternative treatment. The treatment period has a variable duration from a minimum of 60 weeks (for the last subject randomized) to a maximum of 156 weeks for the first subjects randomized in the trial and includes a gradual up-titration of ponesimod from a 2 mg starting dose to a 20 mg maintenance dose over a period of 14 days. The total duration of the study will be approximately up to 167 weeks.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed prior to initiation of any study-mandated procedure.
  • Women of must have a negative pregnancy test and use reliable methods of
  • Presenting with a diagnosis of MS as defined by the revised (2010) McDonald Diagnostic Criteria for MS with relapsing course from onset (i.e., relapsing-remitting multiple sclerosis (RRMS), or secondary progressive multiple sclerosis (SPMS) with superimposed relapses).
  • Ongoing treatment with DMF for at least 6 months prior to screening
  • Active disease after at least 3 months of DMF treatment
  • Ambulatory and with an EDSS score between 0 and 6.0 (inclusive).

Exclusion criteria

Exclusion Criteria:

  • Lactating or pregnant women and women intending to become pregnant during the study.
  • Presenting with a diagnosis of MS with progressive course from onset (i.e., primary progressive MS or progressive relapsing MS).
  • Evidence of a relapse of MS with onset within 30 days prior to baseline EDSS assessment.
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
136 participants (actual)

Study arms

  • Experimental
    Ponesimod

    Ponesimod

    Drug: Ponesimod

  • Placebo comparator
    Placebo

    Placebo

    Other: Placebo

Interventions

  • One tablet of ponesimod 20 mg administered orally once daily in the morning from Day 15 to EOT. To reduce the first-dose effect of ponesimod, an uptitration scheme will be implemented from Day 1 to Day 14 (with dose strength increasing from 2 mg to 20 mg).

  • OtherPlacebo

    One tablet of matching placebo administered orally once daily in the morning

06

What researchers measure

Primary outcomes

  1. Annualized Confirmed Relapse Rate (ARR)

    Relapse: occurrence of acute episode of one or more new or worsened symptoms of Multiple sclerosis (MS), not associated with fever/infection and lasting 24 hours after stable 30 days period. Confirmed relapse: increase from baseline at least 0.5 point Expanded Disability Status Scale (EDSS) score or increase of one point in one, two or three Functional Systems (FS), excluding bowel/bladder and cerebral/mental FS. EDSS and FS scores are based on neurological examination for assessing its impairment in MS. Among eight FS, seven are ordinal clinical rating scales ranging from 0-5 or 6 with higher scale indicates overall functional impairment assessing Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel/Bladder and Cerebral functions. Rating individual FS scores is used to rate EDSS in conjunction with observations and information concerning gait and use of assistance. EDSS is ordinal clinical rating scale ranging from 0 (normal neurological examination) to 10(death due to MS).

    Time frame: Through study completion, an average of 68 weeks

Secondary outcomes

  1. Percentage of Participants With 12-Week Confirmed Disability Accumulation (CDA) as Assessed by Kaplan Meier Estimate at Week 96

    Percentage of participants with 12-week CDA as assessed by Kaplan Meier estimate at week 96 was defined as an increase of at least 1.5 in Expanded Disability Status Scale (EDSS) for participants with a baseline EDSS score of 0.0 or an increase of at least 1.0 in EDSS for participants with a baseline EDSS score of 1.0 to 5.0, or an increase of at least 0.5 in EDSS for participants with a baseline EDSS score greater than or equal to (\>=) 5.5, which was confirmed after 12 weeks. Baseline EDSS was defined as the last EDSS score recorded prior to randomization. EDSS is an ordinal clinical rating scale ranging from 0 (normal neurological examination) to 10 (death due to MS).

    Time frame: Week 96

  2. Percentage of Participants Experiencing a Confirmed Relapse as Assessed by Kaplan Meier Estimate at Week 96

    Percentage of participants experiencing a confirmed relapse as assessed by Kaplan Meier estimate at week 96 was reported. The time to first confirmed relapse (in days) is defined as \[Date of first confirmed relapse minus Date of randomization plus 1\] in days. Relapse: Occurrence of acute episode of one or more new symptoms or worsened symptoms of Multiple sclerosis (MS), not related with fever/infection and lasting 24 hours after 30 days stable period.

    Time frame: Week 96

  3. Number of Participants With Adverse Events (AEs) as a Measure of Safety and Tolerability

    An AE is any untoward medical event that occurs in a participants administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.

    Time frame: Up to 147 Weeks

07

Results

Posted May 18, 2021
Limitations and caveats
Due to slow recruitment rate the study was considered futile by the Independent Data Monitoring Committee and the sponsor agreed to prematurely terminate the study. Due to this premature termination of study, the insufficient sample size did not allow to detect the differences for the main efficacy endpoints. The safety profile of ponesimod as add-on to DMF therapy could not be fully characterized due to limited data.

Participant flow

Participant flow — Overall Study
MilestonePonesimod Plus Dimethyl Fumarate (DMF)Placebo Plus Dimethyl Fumarate (DMF)
Started6868
Treated6768
Randomized analysis set6868
Completed00
Not completed6868
Withdrew: Death01
Withdrew: Physician decision33
Withdrew: Withdrawal by subject157
Withdrew: Sponsor's decision5057

Outcome measures

PrimaryAnnualized Confirmed Relapse Rate (ARR)

Relapse: occurrence of acute episode of one or more new or worsened symptoms of Multiple sclerosis (MS), not associated with fever/infection and lasting 24 hours after stable 30 days period. Confirmed relapse: increase from baseline at least 0.5 point Expanded Disability Status Scale (EDSS) score or increase of one point in one, two or three Functional Systems (FS), excluding bowel/bladder and cerebral/mental FS. EDSS and FS scores are based on neurological examination for assessing its impairment in MS. Among eight FS, seven are ordinal clinical rating scales ranging from 0-5 or 6 with higher scale indicates overall functional impairment assessing Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel/Bladder and Cerebral functions. Rating individual FS scores is used to rate EDSS in conjunction with observations and information concerning gait and use of assistance. EDSS is ordinal clinical rating scale ranging from 0 (normal neurological examination) to 10(death due to MS).

Time frame:
Through study completion, an average of 68 weeks
Reported as:
Mean · Relapses per year
Annualized Confirmed Relapse Rate (ARR)
Relapses per yearPonesimod Plus Dimethyl Fumarate (DMF)Placebo Plus Dimethyl Fumarate (DMF)
Annualized Confirmed Relapse Rate (ARR)0.237 (0.144 to 0.391)0.187 (0.109 to 0.322)
Statistical analysis
  • Ponesimod Plus Dimethyl Fumarate (DMF) vs Placebo Plus Dimethyl Fumarate (DMF) · Negative binomial regression · p = 0.5252 · Treatment effect (rate ratio): 1.270 · 95% CI 0.608 to 2.654Rate ratio is ponesimod 20 mg / DMF versus placebo /DMF
SecondaryPercentage of Participants With 12-Week Confirmed Disability Accumulation (CDA) as Assessed by Kaplan Meier Estimate at Week 96

Percentage of participants with 12-week CDA as assessed by Kaplan Meier estimate at week 96 was defined as an increase of at least 1.5 in Expanded Disability Status Scale (EDSS) for participants with a baseline EDSS score of 0.0 or an increase of at least 1.0 in EDSS for participants with a baseline EDSS score of 1.0 to 5.0, or an increase of at least 0.5 in EDSS for participants with a baseline EDSS score greater than or equal to (\>=) 5.5, which was confirmed after 12 weeks. Baseline EDSS was defined as the last EDSS score recorded prior to randomization. EDSS is an ordinal clinical rating scale ranging from 0 (normal neurological examination) to 10 (death due to MS).

Time frame:
Week 96
Reported as:
Number · Percentage of participants with a CDA.
Percentage of Participants With 12-Week Confirmed Disability Accumulation (CDA) as Assessed by Kaplan Meier Estimate at Week 96
Percentage of participants with a CDA.Ponesimod Plus Dimethyl Fumarate (DMF)Placebo Plus Dimethyl Fumarate (DMF)
Percentage of Participants With 12-Week Confirmed Disability Accumulation (CDA) as Assessed by Kaplan Meier Estimate at Week 9618.7 (8.7 to 37.6)11.9 (4.6 to 28.8)
SecondaryPercentage of Participants Experiencing a Confirmed Relapse as Assessed by Kaplan Meier Estimate at Week 96

Percentage of participants experiencing a confirmed relapse as assessed by Kaplan Meier estimate at week 96 was reported. The time to first confirmed relapse (in days) is defined as \[Date of first confirmed relapse minus Date of randomization plus 1\] in days. Relapse: Occurrence of acute episode of one or more new symptoms or worsened symptoms of Multiple sclerosis (MS), not related with fever/infection and lasting 24 hours after 30 days stable period.

Time frame:
Week 96
Reported as:
Number · Percentage of Participants
Percentage of Participants Experiencing a Confirmed Relapse as Assessed by Kaplan Meier Estimate at Week 96
Percentage of ParticipantsPonesimod Plus Dimethyl Fumarate (DMF)Placebo Plus Dimethyl Fumarate (DMF)
Percentage of Participants Experiencing a Confirmed Relapse as Assessed by Kaplan Meier Estimate at Week 9633.6 (19.5 to 53.8)25.7 (13.4 to 46.1)
SecondaryNumber of Participants With Adverse Events (AEs) as a Measure of Safety and Tolerability

An AE is any untoward medical event that occurs in a participants administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.

Time frame:
Up to 147 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) as a Measure of Safety and Tolerability
ParticipantsPonesimod Plus Dimethyl Fumarate (DMF)Placebo Plus Dimethyl Fumarate (DMF)
Number of Participants With Adverse Events (AEs) as a Measure of Safety and Tolerability4853

Adverse events

Collected over Up to End of treatment + 15 days (maximum up to 147 Weeks). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ponesimod Plus Dimethyl Fumarate (DMF)0/67 (0%)6/67 (9%)45/67 (67.2%)
Placebo Plus Dimethyl Fumarate (DMF)1/68 (1.5%)7/68 (10.3%)41/68 (60.3%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventPonesimod Plus Dimethyl Fumarate (DMF)Placebo Plus Dimethyl Fumarate (DMF)
Gastroenteritis BacterialInfections and infestations1/670/68
Multiple InjuriesInjury, poisoning and procedural complications1/670/68
Procedural NauseaInjury, poisoning and procedural complications1/670/68
Road Traffic AccidentInjury, poisoning and procedural complications1/670/68
Testicle AdenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/670/68
SeizureNervous system disorders1/670/68
Status EpilepticusNervous system disorders1/670/68
Urinary RetentionRenal and urinary disorders1/670/68
Right Ventricular FailureCardiac disorders0/671/68
InfluenzaInfections and infestations0/671/68
Most frequent other events
Showing 10 of 65
Most frequent other events
EventPonesimod Plus Dimethyl Fumarate (DMF)Placebo Plus Dimethyl Fumarate (DMF)
NasopharyngitisInfections and infestations6/6713/68
DizzinessNervous system disorders7/671/68
Upper Respiratory Tract InfectionInfections and infestations3/677/68
ArthralgiaMusculoskeletal and connective tissue disorders4/677/68
HeadacheNervous system disorders6/676/68
Back PainMusculoskeletal and connective tissue disorders2/676/68
ParaesthesiaNervous system disorders0/676/68
BronchitisInfections and infestations5/673/68
Urinary Tract InfectionInfections and infestations4/675/68
FatigueGeneral disorders4/674/68

Baseline characteristics

Randomized Analysis Set included all participants who were randomized in this study.

Age, Categorical
Age, Categorical(Participants)Ponesimod Plus Dimethyl Fumarate (DMF)Placebo Plus Dimethyl Fumarate (DMF)Total
<=18 years000
Between 18 and 65 years6868136
>=65 years000
Age, Continuous
Age, Continuous(years)Ponesimod Plus Dimethyl Fumarate (DMF)Placebo Plus Dimethyl Fumarate (DMF)Total
Mean37.8 ± 9.138.1 ± 9.137.9 ± 9.07
Sex: Female, Male
Sex: Female, Male(Participants)Ponesimod Plus Dimethyl Fumarate (DMF)Placebo Plus Dimethyl Fumarate (DMF)Total
Female434689
Male252247
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ponesimod Plus Dimethyl Fumarate (DMF)Placebo Plus Dimethyl Fumarate (DMF)Total
Hispanic or Latino426
Not Hispanic or Latino6161122
Unknown or Not Reported358
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ponesimod Plus Dimethyl Fumarate (DMF)Placebo Plus Dimethyl Fumarate (DMF)Total
Asian011
Black or African American314
Other022
Unknown or Not Reported112
White6463127
Region of Enrollment
Region of Enrollment(Participants)Ponesimod Plus Dimethyl Fumarate (DMF)Placebo Plus Dimethyl Fumarate (DMF)Total
AUSTRIA5712
BELGIUM202
BULGARIA224
CANADA011
CZECH REPUBLIC161733
FRANCE4610
GERMANY4610
GREECE4610
HUNGARY101
ITALY549
MEXICO101
POLAND459
PORTUGAL101
RUSSIAN FEDERATION426
SPAIN235
UNITED KINGDOM549
UNITED STATES8513
08

Study locations

119 sites
  • UAB Dpt of Neurology
    Birmingham, Alabama 35233, United States
  • Neuro-Pain Medical Center
    Fresno, California 93710, United States
  • SC3 Research - Pasadena
    Pasadena, California 91105, United States
  • Care Access Research - Santa Clarita
    Santa Clarita, California 91321, United States
  • Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
    Torrance, California 90502, United States
  • University of Colorado Hospital
    Aurora, Colorado 80045, United States
  • Mountain View Clinical Research, Inc
    Denver, Colorado 80209, United States
  • Associated Neurologists
    Danbury, Connecticut 06810, United States
  • Bradenton Research Center
    Bradenton, Florida 34205, United States
  • Neurology Associates - MS Center of Greater Orlando
    Maitland, Florida 32751, United States
  • Neurology Assoc of Ormond Beach - CNS Trials
    Ormond Beach, Florida 32174, United States
  • Suncoast Neuroscience Associates, Inc
    Saint Petersburg, Florida 33713, United States
  • The MS Center of Vero Beach
    Vero Beach, Florida 32960, United States
  • Fort Wayne Neurological Center - North Office
    Fort Wayne, Indiana 46825, United States
  • University of Kansas Med Center
    Kansas City, Kansas 66160, United States
  • MidAmerica Neuroscience Research Foundation/Rowe Neurology
    Lenexa, Kansas 66214, United States
  • Henry Ford Health System - Neurology
    Detroit, Michigan 48202, United States
  • Univ of New Mexico - Health Sciences Center
    Albuquerque, New Mexico 87131, United States
  • NYU Langone Medical Center - MS Comprehensive Care Center
    New York, New York 10016, United States
  • Riverhills Healthcare, Inc.
    Cincinnati, Ohio 45212, United States
  • OhioHealth Research Institute
    Columbus, Ohio 43214, United States
  • Neurology and Neuromuscular Center
    Oklahoma City, Oklahoma 73102, United States
  • Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Thomas Jefferson University Hospital - Dpt Neurology MS Center
    Philadelphia, Pennsylvania 19107, United States
  • Advanced Neuroscience Institute
    Franklin, Tennessee 37064, United States
  • Neurology Center of San Antonio
    San Antonio, Texas 78258, United States
  • Austin Health - Neuro-Immunology Clinical Research, Education and Support Service
    Heidelberg, Victoria 3084, Australia
  • MS Ambulanz Maida
    Wien, 1010, Austria
  • Medizinische Universität Wien, Universitätsklinik für Neurologie
    Wien, 1090, Austria
  • Hospital universitair Brussels_neurology department
    Brussels, 1090, Belgium
  • Hospital - Universitair Gent __Neurology Department
    Gent, 9000, Belgium
  • Hospital - Revalidatie & MS Centrum Overpelt_Neurology Department
    Overpelt, 3900, Belgium
  • "Multiprofile Hospital for Active Treatment of Neurology and Psychiatry - Sveti Naum" EAD - Neurology Clinic for Movement Disorders
    Sofia, 1113, Bulgaria
  • "University Multiprofile Hospital for Active Treatment - Alexandrovska" EAD, Neurology Clinic
    Sofia, 1431, Bulgaria
  • University Multiprofile Hospital for Active Treatment "Sv. Ivan Rilski" EAD, Neurology Clinic
    Sofia, 1431, Bulgaria
  • University of Alberta
    Edmonton, T6G 1Z1, Canada
  • Fakultní nemocnice u sv. Anny Brno, RS Centrum
    Brno, 656 91, Czechia
  • Fakultní nemocnice Hradec Králové, Neurologická klinika
    Hradec Králové, 500 05, Czechia
  • Nemocnice Jihlava, Neurologické oddělení
    Jihlava, 586 33, Czechia
  • Pardubicka krajska nemocnice, MS Centrum
    Pardubice, 532 03, Czechia
  • Krajská zdravotní a.s. - Nemonice Teplice o.z., RS Centrum
    Teplice, 415 29, Czechia
  • Aalborg Universitetshospital, Skleroseklinikken Neurologisk afdelning
    Aalborg, 9000, Denmark
  • Glostrup Hospital, Neurologisk afdelning
    Glostrup, 2600, Denmark
  • Hôpital Avicenne, Service de Neurologie
    Bobigny, 93000, France
  • Hosp Gabriel Montpied, Dept Neurology
    Clermont Ferrand, 63003, France
  • Centre Hospitalier Sud Francilien - Service de Neurologie
    Corbeil-Essonnes, 91100, France
  • CHU de Dijon - Hôpital François Miterrand, Service de Neurologie
    Dijon, 21079, France
  • CHRU de Lille - Hôpital Roger Salengro, Service de Neurologie
    Lille, 59037, France
  • Hopital Gui de Chauliac - CHU Montpellier
    Montpellier, 34295, France
  • Hôpital Central - CHU Nancy, Département Neurologie
    Nancy, 54035, France
  • Hôpital Universitaire Carémeau, Service de Neurologie
    Nimes, 30029, France
  • CHI POISSY-Saint Germay en Laye_Service de Neurologie et Réeducation
    Poissy, 78303, France
  • Hosp Pontchaillou, Dept Cardiology
    Rennes, 35033, France
  • Hosp Charles Nicolle Dept Neurology
    Rouen, 76000, France
  • Zentrum für klinische Forschung Dr. med. Irma Schöll
    Bad Homburg, 61348, Germany
  • Neurologische Klinik und Poliklinik - Universitätsklinikum Carl Gustav Carus, Zentrum für klinische Neurowissenschaften
    Dresden, 01307, Germany
  • Helios Klinikum Erfurt
    Erfurt, 99089, Germany
  • Universitätsklinikum Giessen Klinik und Poliklinik für Neurologie
    Giessen, 35385, Germany
  • Universitätsmedizin Greifswald - Körperschaft des öffentlichen Rechts - Klinik und Poliklinik für Neurologie
    Greifswald, 17475, Germany
  • Medizinische Hochschule Hannover, Neurologie
    Hannover, 30625, Germany
  • AFL Arzneimittelforschung Leipzig GmbH
    Leipzig, 04107, Germany
  • Universitätsklinikum Münster, Klinik für Allgemeine Neurologie
    Münster, 48149, Germany
  • Medizinzentrum Siegerland Weidenau
    Siegen, 57076, Germany
  • NeuroPoint GmbH, Gesellschaft für vorbeugende Gesundheitspflege
    Ulm, 89073, Germany
  • Gemeinschaftspraxis Dr. med. Joachim Springub / Wolfgang Schwarz, Studienzentrum Nord-West (Study Center)
    Westerstede, 26655, Germany
  • Naval Hospital of Athens - Neurology Dpt
    Athens, 11521, Greece
  • 401 Military Hospital of Athens - Neurology Dept
    Athens, 11525, Greece
  • Aeginition Hospital - Neurology Department
    Athens, 11528, Greece
  • Medical Center of Athens - Neurology Dpt
    Marousi, 15125, Greece
  • General Hospital of Thessaloniki
    Thessaloniki, 57010, Greece
  • Uzsoki utcai Kórház, Neurológiai Osztály
    Budapest, 1145, Hungary
  • Valeomed EGÉSZSÉGÜGYI KÖZPONT
    Esztergom, 2500, Hungary
  • Pest Megyei Flór Ferenc Kórház, Neurológia és Stroke ambulancia
    Kistarcsa, 2143, Hungary
  • Fondazione Istituto San Raffaele , Unità Operativa di Neurologia
    Cefalù, 90015, Italy
  • Università degli Studi di Firenze - Azienda Ospedaliero Universitaria Careggi - CTO - SOD Neurologia 2
    Firenze, 50139, Italy
  • AOU San Martino di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DINOGMI)
    Genova, 16132, Italy
  • Istituto Neurologico Carlo Besta, UOC Neurologia 4, Neuroimmunologia e Malattie Neuromuscolari, Centro Sclerosi Multipla
    Milano, 20133, Italy
  • Azienda Ospedaliera Universitaria (AOU) "Federico II" - Centro Regionale Per la Sclerosi Multipla c/o Clinica Neurologica II - Dipartimento di Scienze
    Napoli, 80131, Italy
  • AOU Università degli Studi della Campania L. Vanvitelli - I° Policlinico - DAI di Medicina Interna e Specialistica CS, Centro Sclerosi Multipla
    Napoli, 80138, Italy
  • Azienda Ospedaliero Universitaria San Luigi Gonzaga - Centro Sclerosi Multipla CRESM
    Orbassano, 10043, Italy
  • IRCCS NEUROMED - Istituto Neurologico Mediterraneo - Unità Operativa di Neurologia I
    Pozzilli, 86077, Italy
  • Azienda Ospedaliera S. Andrea di Roma - Unità Operativa Complessa di Neurologia
    Roma, 00189, Italy
  • Azienda Ospedaliera Universitaria Senese - Dipartimento di Scienze Neurologiche e neurosensoriali - UOSA Neurologia Sperimentale
    Siena, 53100, Italy
  • Unidad de Investigacion en Salud de Chihuahua SC, Médica Sur, Unidad de Neurociencias
    Tlalpan, DF 14050, Mexico
  • Desarrollo Ético en Investigación Clínica S.C .
    Guadalajara, Jalisco 44500, Mexico
  • Axis Heilsa S. de R.L. de C.V. (Althian)
    Nuevo Leon, Monterrey 64060, Mexico
  • Unidad de Investigación de Salud en Chihuahua
    Chihuahua, 31203, Mexico
  • Uniwersytecki Szpital Kliniczny w Bialymstoku, Klinika Neurologii i Oddziat Udarowy
    Bialystok, 15-276, Poland
  • B&B Robert Bonek, Pawel Bochniak S.C
    Bydgoszcz, 85-795, Poland
  • COPERNICUS - Podmiot Leczniczy Sp. z o.o.
    Gdansk, 80-803, Poland
  • Centrum Terapii SM
    Katowice, 40-571, Poland
  • Neuro-Medic Janusz Zbrojkiewicz Poradnia Weilospecjalistyczna
    Katowice, 40-752, Poland
  • Centrum Kompleksowej Rehabilitacji
    Konstancin-Jeziorna, 05-510, Poland
  • Centrum Opieki Zdrowotnej Orkan - Med.
    Ksawerów, 95-054, Poland
  • Instytut Psychiatrii i Neurologii, II Klinika Neurologiczna
    Warszawa, 02-957, Poland
  • WroMedica, J. Bielicka A. Strzałkowska SC
    Wroclaw, 51-685, Poland
  • Centro Hospitalar de Lisboa Central
    Lisboa, 1169-050, Portugal
  • Hospital de Santa Maria - Neurology Department
    Lisboa, 1649-035, Portugal
  • Centro Hospitalar de São João, E.P.E. - Hospital de São João - Neurology Department
    Porto, 4200-319, Portugal
  • State Budgetary Healthcare Institution Regional Clinical Hospital No 3
    Chelyabinsk, 454021, Russian Federation

Showing the first 100 of 119 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2017 to primary completion in Mar 2020, 35 months.

Results were first posted in May 2021, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2016
First posted
Sep 20, 2016
StartActual
Mar 30, 2017
Primary completionActual
Mar 26, 2020
CompletionActual
Mar 26, 2020
Results first posted
May 18, 2021
Last update
May 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02907177
Lead sponsor
Actelion
Responsible party
Sponsor
First posted
Sep 20, 2016
Start date
Mar 30, 2017
Primary completion
Mar 26, 2020
Completion
Mar 26, 2020
Results posted
May 18, 2021
Last update
May 18, 2021

Study contacts

Tatiana Scherz, MD, PhD
study director · Actelion

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ponesimod

Start the discussion